Inquirer on MSN1d
World’s first anti-depression nasal spray receives FDA approvalThe US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...
Johnson & Johnson reported that Spravato treated over 100,000 patients in 77 countries worldwide, including roughly 80,000 in ...
GlobalData on MSN15d
J&J’s Spravato receives FDA label expansion for depression monotherapyJohnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy treatment for major depressive disorder (MDD) in adults who do not respond to ...
Verywell Health on MSN8d
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant DepressionPeople with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
Kelsey Warren [email protected] 609 218 4053 Investor contact: Lauren Johnson [email protected] ...
The Sackler family, owners of Purdue Pharma, reached a $7.4 billion settlement to resolve mass opioid litigation. The Department of Justice filed a civil lawsuit against Walgreens over allegations it ...
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback